Syneron Medical has received the US Food and Drug Administration (FDA) approval for its new elos Plus multi-platform device.
The new elos Plus device utilizes the company’s proprietary elos technology of optical energy and bi-polar radiofrequency and features intuitive fifteen-inch touch screen which provide unparalleled ease-of-use through its simple guided treatment modes for all applications.
Using full range of up to eight in-demand aesthetic applicators including the company’s Sublative and Sublime applicators, the elos system can be customized or upgraded.
Syneron chief executive officer Louis P. Scafuri said the vision for the elos Plus has the capacity to deliver a full range of aesthetic treatments and is equipped with the most advanced features for optimum speed, safety and performance.
"We believe elos Plus will appeal to a broad range of customers and allow them to customize their investment to meet the demand of their individual practice," Scafuri added.
The elos Plus system can be used in any aesthetic practices, when equipped with its proprietary Sublative iD, Active Dermal Monitoring and Intelligent Feedback system (IFS).
South Coast Dermatology Institutes medical director and dermatologist Vince Afsahi said, "The intuitive and interactive user interface of the elos Plus improves user experience, while the additional safety measures such as the IFS, which is now available on all applications, ensures maximum treatment delivery without compromising patient safety or comfort."